IDRA-21
Tried IDRA-21? Be part of the collective knowledge. Share your experience - your insights help others on their journey.
What Is IDRA-21?
IDRA-21 is a benzothiadiazine derivative and a positive allosteric modulator of the glutamatergic AMPA receptor. It works by attenuating the rapid desensitization of these receptors, thereby increasing excitatory synaptic strength and promoting long-term potentiation in the brain.
IDRA-21 Research & Studies
01 The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys ▸
This study found that IDRA-21 significantly improved task accuracy in monkeys for up to 48 hours after a single dose, highlighting its potential for long-lasting cognitive enhancement.
View Study (PubMed)02 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys ▸
Researchers demonstrated that IDRA-21 effectively reverses learning deficits induced by GABA-enhancing drugs like alprazolam.
View Study (PubMed)03 Effect of the AMPA receptor modulator IDRA 21 on LTP in hippocampal slices ▸
The study suggests IDRA-21 promotes long-term potentiation (LTP), the cellular basis for memory, by enhancing AMPA receptor-mediated currents.
View Study (PubMed)04 7-Chloro-3-methyl-3-4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA 21): a benzothiadiazine derivative that enhances cognition by attenuating AMPA receptor desensitization ▸
Research in rats showed that oral administration of IDRA-21 significantly improved performance in water maze tasks and passive avoidance tests.
View Study (PubMed)05 The diazoxide derivative IDRA 21 enhances ischemic hippocampal neuron injury ▸
This critical study warns that IDRA-21 can worsen neuronal damage following a stroke or global ischemia due to excessive AMPA receptor activation.
View Study (PubMed)IDRA-21 User Reviews & Experiences
*Based on large scale analysis of publicly available user experiences
Users generally report significant memory and focus benefits, but a high level of caution exists regarding potential excitotoxicity and long-term safety.
IDRA-21 Benefits, Dosage & Side Effects
- Memory Enhancement: Users report improved short-term and rote memorization capabilities, described as seeing ideas 'encoded'.
- Increased Focus: Reported to produce an intense, non-stimulant focus often described as an 'electric' or 'psychedelic' tingle.
- Long-Lasting Clarity: Unlike typical nootropics, effects are noted to persist for 24-48 hours due to the drug's long half-life.
- Reversal of Impairment: Potential to clear brain fog and assist in recovery from cognitive decline caused by stress or substance use.
- Potency: Frequently compared to aniracetam but regarded as significantly more potent (up to 10-30 times).
- Synergy with Other Nootropics: Often stacked with PRL-8-53 or Racetams to maximize memory retention for exams.
- Task Difficulty: Research suggests it is most effective at improving performance on complex or 'difficult' cognitive tasks rather than simple ones.
- Variable Response: While highly effective for some, others find the stimulation 'weird' or unsettling compared to traditional stimulants.
- Standard Oral Dose: Most users report taking between 5mg and 10mg per day.
- Frequency: Due to the long half-life (noted in research as up to 48 hours), many users dose every 2-3 days rather than daily.
- Microdosing: Some users start as low as 3mg to assess sensitivity and mitigate the risk of over-excitation.
- Intranasal Use: A few users experiment with 10mg intranasaly, though there is no formal research supporting this route.
- Excitotoxicity Risk: The primary concern is permanent neuronal damage if taken during high-stress states, stroke, or seizures.
- Scalp Tingling: A common user-reported sensation described as an electric or vibrating feeling on the scalp.
- Headaches: Some users report pressure or 'brain fog' if Choline levels are not managed while using AMPA modulators.
- Increased Ischemic Damage: Scientific evidence indicates it can worsen brain damage during oxygen-deprived events like a stroke.
- Research Chemical Status: Primarily sold through specialized nootropic sources as a research compound rather than a dietary supplement.
- Regulatory: Not FDA-approved for human consumption; strictly categorized as a laboratory research chemical in many regions.
Related Compounds
Community Reviews
Share your experience with IDRA-21 and help others make informed decisions.
Write a Review
Sign in to leave a review